Switch theme
Sign up to access all valuation multiples
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
1991
3.6K+
LTM Revenue $1.4B
LTM EBITDA $375M
$3.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dermapharm has a last 12-month revenue (LTM) of $1.4B and a last 12-month EBITDA of $375M.
In the most recent fiscal year, Dermapharm achieved revenue of $1.4B and an EBITDA of $376M.
Dermapharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dermapharm valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| Gross Profit | $895M | XXX | $899M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $375M | XXX | $376M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $266M | XXX | $252M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $139M | XXX | $133M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $986M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, Dermapharm's stock price is EUR 35 (or $40).
Dermapharm has current market cap of EUR 1.9B (or $2.2B), and EV of EUR 2.7B (or $3.2B).
See Dermapharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.2B | $2.2B | XXX | XXX | XXX | XXX | $2.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, Dermapharm has market cap of $2.2B and EV of $3.2B.
Dermapharm's trades at 2.3x EV/Revenue multiple, and 8.5x EV/EBITDA.
Equity research analysts estimate Dermapharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dermapharm has a P/E ratio of 15.6x.
See valuation multiples for Dermapharm and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 8.5x | XXX | 8.5x | XXX | XXX | XXX |
| EV/EBIT | 12.0x | XXX | 12.6x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.6x | XXX | 16.3x | XXX | XXX | XXX |
| EV/FCF | 16.9x | XXX | 16.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDermapharm's last 12 month revenue growth is 2%
Dermapharm's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Dermapharm's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dermapharm's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dermapharm and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dermapharm acquired XXX companies to date.
Last acquisition by Dermapharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Dermapharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dermapharm founded? | Dermapharm was founded in 1991. |
| Where is Dermapharm headquartered? | Dermapharm is headquartered in Germany. |
| How many employees does Dermapharm have? | As of today, Dermapharm has 3.6K+ employees. |
| Is Dermapharm publicy listed? | Yes, Dermapharm is a public company listed on FRA. |
| What is the stock symbol of Dermapharm? | Dermapharm trades under DMP ticker. |
| When did Dermapharm go public? | Dermapharm went public in 2018. |
| Who are competitors of Dermapharm? | Similar companies to Dermapharm include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Dermapharm? | Dermapharm's current market cap is $2.2B |
| What is the current revenue of Dermapharm? | Dermapharm's last 12 months revenue is $1.4B. |
| What is the current revenue growth of Dermapharm? | Dermapharm revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Dermapharm? | Current revenue multiple of Dermapharm is 2.3x. |
| Is Dermapharm profitable? | Yes, Dermapharm is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dermapharm? | Dermapharm's last 12 months EBITDA is $375M. |
| What is Dermapharm's EBITDA margin? | Dermapharm's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Dermapharm? | Current EBITDA multiple of Dermapharm is 8.5x. |
| What is the current FCF of Dermapharm? | Dermapharm's last 12 months FCF is $188M. |
| What is Dermapharm's FCF margin? | Dermapharm's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Dermapharm? | Current FCF multiple of Dermapharm is 16.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
